-
公开(公告)号：US11820781B2
公开(公告)日：2023-11-21
申请号：US17111454
申请日：2020-12-03
发明人： Aileen Kelly , Arthur T. Sands
IPC分类号： A61P35/00 , A61P19/00 , A61P37/00 , C07D487/10 , C07D498/10 , C07D401/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D491/107
CPC分类号： C07D498/10 , C07D401/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/107
摘要： This disclosure relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The description also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
-
公开(公告)号：US11530229B2
公开(公告)日：2022-12-20
申请号：US16875917
申请日：2020-05-15
发明人： Arthur T. Sands , Neil F. Bence , Christoph W. Zapf , Frederick Cohen , Chenbo Wang , Thomas Cummins , Hiroko Tanaka , Hunter Shunatona , Mario Cardozo , Dahlia Weiss , Jennifa Gosling
IPC分类号： C07D498/08 , C07D403/12 , C07D403/14 , C07D413/14 , C07D471/04
摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
-
公开(公告)号：US11479556B1
公开(公告)日：2022-10-25
申请号：US15734774
申请日：2019-10-14
发明人： Daniel W. Robbins , Arthur T. Sands , Joel McIntosh , Jeffrey Mihalic , Jeffrey Wu , Daisuke Kato , Dahlia Weiss , Ge Peng
IPC分类号： C07D487/10 , C07D401/14 , C07D471/10 , C07D417/14 , C07D413/14 , C07D491/107 , C07D498/10 , C07D487/04
摘要： The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
-
公开(公告)号：US12049471B2
公开(公告)日：2024-07-30
申请号：US18068195
申请日：2022-12-19
发明人： Arthur T. Sands , Neil F. Bence , Christoph W. Zapf , Frederick Cohen , Chenbo Wang , Thomas Cummins , Hiroko Tanaka , Hunter Shunatona , Mario Cardozo , Dahlia Weiss , Jennifa Gosling
IPC分类号： C07D498/08 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D491/08
CPC分类号： C07D498/08 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D491/08
摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
-
公开(公告)号：US11866442B2
公开(公告)日：2024-01-09
申请号：US17876433
申请日：2022-07-28
发明人： Daniel W. Robbins , Arthur T. Sands , Joel McIntosh , Jeffrey Mihalic , Jeffrey Wu , Daisuke Kato , Dahlia Weiss , Ge Peng
IPC分类号： C07D487/10 , C07D413/14 , C07D491/107 , C07D498/10 , C07D471/10 , C07D401/14 , C07D417/14 , C07D487/04
CPC分类号： C07D487/10 , C07D401/14 , C07D413/14 , C07D417/14 , C07D471/10 , C07D487/04 , C07D491/107 , C07D498/10
摘要： The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
-
公开(公告)号：US11951133B2
公开(公告)日：2024-04-09
申请号：US17864307
申请日：2022-07-13
发明人： Arthur T. Sands , Neil F. Bence , Christoph W. Zapf , Frederick Cohen , Chenbo Wang , Thomas Cummins , Hiroko Tanaka , Hunter Shunatona , Mario Cardozo , Dahlia Weiss , Jennifa Gosling
IPC分类号： A61K35/17 , A61K31/438 , A61K31/454 , A61K31/4545 , A61K33/243 , A61K35/761 , A61K35/763 , A61K35/768 , A61K38/19 , A61K39/00 , A61K39/39 , A61K39/395 , A61K45/06 , A61N5/10 , A61P35/00 , C07D401/14 , C07D405/14 , C07D471/04 , C07D491/107 , C07F5/02 , C12N5/0783
CPC分类号： A61K35/17 , A61K31/438 , A61K31/454 , A61K31/4545 , A61K33/243 , A61K35/761 , A61K35/763 , A61K35/768 , A61K38/193 , A61K39/0011 , A61K39/39 , A61K39/3955 , A61K45/06 , A61N5/1001 , A61N5/1077 , A61P35/00 , C07D401/14 , C07D405/14 , C07D471/04 , C07D491/107 , C07F5/022 , C12N5/0636 , A61K2039/5152 , C12N2501/2302 , C12N2501/998 , C12N2501/999
摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
-
7.发明公开公开(公告)号：US20230149416A1
公开(公告)日：2023-05-18
申请号：US18049547
申请日：2022-10-25
发明人： Robert J. Brown , Arthur T. Sands
IPC分类号： A61K31/5377 , A61K31/497 , A61K31/506 , A61K9/00 , A61P35/02
CPC分类号： A61K31/5377 , A61K31/497 , A61K31/506 , A61K9/0053 , A61P35/02
摘要： This disclosure relates to BTK inhibitor compounds for treating or preventing cancer by daily oral dosing in human subjects in need thereof. The description also provides BTK inhibitor compounds for degrading BTK in vivo by daily oral dosing in human subjects in need thereof.
-
公开(公告)号：US11464802B2
公开(公告)日：2022-10-11
申请号：US16844953
申请日：2020-04-09
发明人： Arthur T. Sands , Neil F. Bence , Christoph W. Zapf , Frederick Cohen , Chenbo Wang , Thomas Cummins , Hiroko Tanaka , Hunter Shunatona , Mario Cardozo , Dahlia Weiss , Jennifa Gosling
IPC分类号： A61K35/17 , A61P35/00 , A61K33/243 , A61K31/438 , A61K31/454 , A61K31/4545 , A61K35/761 , A61K35/763 , A61K35/768 , A61K38/19 , A61K39/00 , A61K39/39 , A61K39/395 , A61K45/06 , A61N5/10 , C07D401/14 , C07D405/14 , C07D471/04 , C07D491/107 , C07F5/02 , C12N5/0783
摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
-
公开(公告)号：US20200323904A1
公开(公告)日：2020-10-15
申请号：US16844953
申请日：2020-04-09
发明人： Arthur T. Sands , Neil F. Bence , Christoph W. Zapf , Frederick Cohen , Chenbo Wang , Thomas Cummins , Hiroko Tanaka , Hunter Shunatona , Mario Cardozo , Dahlia Weiss
IPC分类号： A61K35/17 , A61K39/395 , A61K45/06 , A61K33/243 , A61K39/00 , A61K39/39 , A61K35/763 , A61K38/19 , A61K35/761 , A61K35/768 , C07D405/14 , A61K31/454 , A61K31/438 , C07D491/107 , C07D401/14 , A61K31/4545 , C07D471/04 , C07F5/02 , A61P35/00 , C12N5/0783 , A61N5/10
摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.013 秒)
